Cartesian Therapeutics IncNASDAQ:RNAC
- LAST PRICE18.2500
- TODAY'S CHANGE (%)-6.0200 (-24.8043%)
- Bid / Lots18.0100/ 30
- Ask / Lots18.2000/ 15
- Open / Previous Close17.9700 / 24.2700
- Day Range
- 52 Week Range
- Volume496,311
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RNAC |
|---|---|---|
| 09:32 ET | 14738 | 17.685 |
| 09:34 ET | 7990 | 18.25 |
| 09:36 ET | 2442 | 18.58 |
| 09:38 ET | 7324 | 18.77 |
| 09:39 ET | 39232 | 18.595 |
| 09:41 ET | 7043 | 18.54 |
| 09:43 ET | 15141 | 18.4 |
| 09:45 ET | 32119 | 18.11 |
| 09:48 ET | 28898 | 17.7431 |
| 09:50 ET | 799 | 17.3485 |
| 09:52 ET | 5269 | 17.5 |
| 09:54 ET | 8135 | 18 |
| 09:56 ET | 3578 | 18.38 |
| 09:57 ET | 400 | 18.63 |
| 09:59 ET | 5286 | 18.962 |
| 10:01 ET | 6316 | 18.215 |
| 10:03 ET | 2435 | 18.615 |
| 10:06 ET | 101 | 18.5895 |
| 10:08 ET | 10450 | 18.825 |
| 10:10 ET | 967 | 18.98 |
| 10:12 ET | 4189 | 18.5935 |
| 10:14 ET | 2798 | 18.445 |
| 10:15 ET | 4640 | 18.1195 |
| 10:17 ET | 2110 | 18.2101 |
| 10:19 ET | 4106 | 18.235 |
| 10:21 ET | 2300 | 18.43 |
| 10:24 ET | 13013 | 18.4123 |
| 10:26 ET | 13050 | 18.74 |
| 10:28 ET | 1035 | 18.74 |
| 10:30 ET | 200 | 18.55 |
| 10:32 ET | 100 | 18.755 |
| 10:33 ET | 400 | 18.76 |
| 10:35 ET | 17394 | 18.8 |
| 10:37 ET | 7811 | 18.68 |
| 10:39 ET | 21819 | 18.8085 |
| 10:42 ET | 5252 | 19.4177 |
| 10:44 ET | 10399 | 18.8799 |
| 10:46 ET | 2618 | 18.3001 |
| 10:48 ET | 524 | 18.8723 |
| 10:50 ET | 682 | 18.445 |
| 10:51 ET | 11451 | 18.5949 |
| 10:53 ET | 400 | 18.67 |
| 10:55 ET | 100 | 18.61 |
| 10:57 ET | 1000 | 18.61 |
| 11:00 ET | 100 | 18.61 |
| 11:02 ET | 250 | 18.7 |
| 11:06 ET | 20617 | 18.33 |
| 11:08 ET | 16009 | 18.41 |
| 11:11 ET | 1433 | 18.525 |
| 11:13 ET | 10350 | 18.4464 |
| 11:15 ET | 2195 | 18.4 |
| 11:18 ET | 5252 | 18.25 |
Today
DJ Cartesian Therapeutics' Descartes-08 Meets Primary Endpoint in Chronic Autoimmune Disorder Trial, from 4 hours ago by Dow Jones
4 hours ago by Dow JonesCartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus, from 5 hours ago by Dow Jones
5 hours ago by Dow JonesCartesian Therapeutics Announces $130 Million Private Placement Equity Financing, from 5 hours ago by Dow Jones
5 hours ago by Dow JonesPress Release: Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing, from 5 hours ago by Dow Jones
5 hours ago by Dow JonesCartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis, from 5 hours ago by Dow Jones
5 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cartesian Therapeutics Inc | 431.9M | -0.4x | --- |
AC Immune SA | 394.8M | -5.9x | --- |
OmniAb Inc | 439.9M | -5.8x | --- |
Taysha Gene Therapies Inc | 455.1M | -1.9x | --- |
Verve Therapeutics Inc | 418.1M | -1.7x | --- |
C4 Therapeutics Inc | 333.7M | -2.0x | --- |
Company Information
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Contact Information
- Headquarters
- 704 Quince Orchard RdGAITHERSBURG, MD, United States 20878
- Phone
- 617-923-1400
- Fax
- 617-924-3454
Executives
- Independent Chairman of the Board
- Carrie Cox
- President, Chief Executive Officer, Director
- Carsten Brunn
- Chief Financial Officer
- Blaine Davis
- Senior Vice President, Head of Manufacturing Operations
- Emily English
- Chief Technology Officer
- Metin Kurtoglu
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $431.9M |
|---|---|
Revenue (TTM) | $25.9M |
Shares Outstanding | 17.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.66 |
EPS | $-48.02 |
Book Value | $-25.87 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 16.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -314.15% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
